Carcinoembryonic antigen (CEA) is released from colon cancer cells into the circulation where it is monitored clinically as an indicator of the recurrence or progression of cancer. We have studied the mechanism of CEA membrane attachment and release using the human colonic adenocarcinoma cell line LS-174T, specimens of human colon cancers, and serum from colon cancer patients. CEA release by cells in vitro and in vivo is associated with the conversion of CEA from a membranebound, hydrophobic molecule to a soluble, hydrophilic form with no apparent decrease in molecular mass. When LS-174T cell membranes were incubated with various buffers, proteases, and phospholipases, the only agents that released CEA and converted it to the hydrophilic form were preparations of phosphatidylinositol-specific phospholipase C (PI-PLC). Both 13Hlethanolamine and I3Hlpalmitate could be incorporated metabolically into CEA but only palmitate was released by treatment with PI-PLC, consistent with the presence of a glycosyl-phosphatidylinositol linkage. PI-PLC treatment also released significant quantities of CEA from living monolayers and from seven human colon cancer specimens. These experiments suggest that cellular CEA is anchored to membranes by a covalent linkage to a membrane phosphatidylinositol molecule, and that an endogenous phospholipase may be important for releasing CEA in vitro and in vivo.
Introduction
Carcinoembryonic antigen (CEA)' is a membrane-bound glycoprotein expressed by cancerous and to some extent by normal epithelial cells of the gastrointestinal tract and certain other organs (1) . Its release by colorectal cancer cells has made serum CEA measurements useful in the management of some patients, but the clinical value of CEA is limited due to the frequent failure of serum concentrations to become elevated until late in the course of colorectal cancer (2) .
It is uncertain why many patients with colon cancer have normal serum CEA levels despite the presence of CEA in their tumors, as determined histochemically (3, 4) . Serum levels are undoubtedly the result of many factors, including the cellular CEA content, the rate of CEA release, and the rate of its clearance from the circulation by the liver (5) . In addition, the abnormal expression of CEA on the basolateral surface of some cancer cells appears to favor the entry of CEA into the serum (6) . Information about the mechanism of glycoprotein release by cancer cells could lead to improved methods for the serological detection of membrane-associated antigens such as CEA.
In the present study, we examined the mechanism of CEA release from the human colon adenocarcinoma cell line LS-1 74T. These cells release approximately 30% of their cellular CEA content into the culture medium per day; hence they provide a useful in vitro model for examining CEA release. We demonstrate here that CEA release is accompanied by a conversion of membrane-bound CEA into a soluble, hydrophilic form which resembles that found in the serum of some patients with colon cancer. Furthermore, we have found that phosphatidylinositol-specific phospholipase C (PI-PLC) efficiently releases CEA from isolated LS-l 74T cell membranes and from specimens of human cancers, whereas a variety of other buffers, proteases, and phospholipases are ineffective. These results suggest that CEA is anchored to cancer cell membranes via a linkage to a glycosyl-phosphatidylinositol moiety, and that in some patients CEA may be released in vivo by the action of an endogenous phospholipase.
Methods
Materials. Trypsin (type IX), a-chymotrypsin (type II), elastase (type III), papain, carboxypeptidase B-DFP, phospholipase C from Bacillus cereus (type III), phospholipase C from Clostridium perfringens (type XIV), phospholipase D from cabbage (type IV), phospholipase A2 from Naja naja, N-benzyloxycarbonyl-L-phenylalanine chloromethylketone (ZPCK), and other biochemicals were obtained from the Sigma Chemical Co. (St. Louis, MO). PI-PLC from Staphylococcus aureus was purified as described elsewhere (7) ; its concentration is expressed as micrograms of protein per milliliter. PI-PLC was also purified from Bacillus thuringiensis (Low et (1, 251 Ci/mmol), [9,10-3H] Cell culture and harvest. LS-174t human colon cancer cells (9) were grown oh plastic tissue culture dishes (Falcon Labware, Oxnard, CA) in Dulbecco's modified Eagle's medium-H21 (DME) supplemented with 5% fetal bovine serum (FBS), penicillin, and streptomycin as previtusly described (10) . Dialyzed FBS was prepared by extensively dialyzing FBS against PBS as 40C. For serum-free experiments, serum was replaced with epidermal growth factor (I ng/ml), glucagon (200 ng/tnl), human transferrin (2 jg/ml), and bovine insulin (5 gg/ml). The possibility of contamination with mycoplasma was excluded by [3H]DNA hybridization probe assay (Gen-Probe Inc, San Diego, CA). Culture medium containing released CEA was produced by incubating confluent monolayers with medium for up to 24 h using 3 and 15 ml of medium for 35-and 100-mm dishes, respectively. The medium was then made 0.1 mM phenylmethylsulfonyl fluoride (PMSF), centrifuged at 600 g for 10 min to remove floating cells, and stored at -60'C until used. When necessary, medium was concentrated 15-fold at 4VC using an Amicon chamber with a PM 10 membrane (Amicon Corp., Lexington, MA), a process requiring 90 min.
Cell homogenate was prepared by washing the monolayers three times with iced isotonic phosphate-buffered saline (PBS, pH 7.4), scraping with a rubber policeman, incubating the cells in 10 mM Tris-HCI (pH 7.4) on ice for 10 min, and performing 30 strokes with a Dounce homogenizer. Cell membranes were prepared under sterile conditions by centrifuging cell homogenates for 1 h at 100,000 g at 4VC in a 50 Ti rotor (Beckman Instruments, Inc., Fullerton, CA). The pellet was reconstituted in 10 mM Tris-HCI, pH 7.4, 100 mM NaCi (buffer A) to a protein concentration of 2.3 mg/ml, and frozen at -60°C.
Incorporation of radioactive precursors. Incorporation of radioactive cysteine, palmitate, and ethanolamine was performed by first incubating confluent LS-174T cells in 60-mm dishes overnight in DME containing 5% dialyzed FBS but omitting the nonradioactive form of the appropriate precursor. The cells were then incubated 24 h at 37°C. The monolayers were then washed extensively with iced DME, scraped, and sonicated, and cell membranes were prepared and stored as described above.
Biochemical assays. Lactate dehydrogenase (LDH) was measured using the method of Bergmeyer et al. (1 1) . Protein content was assayed by dye binding (12) using reagents from Bio-Rad Laboratories and bovine serum albumin (BSA) as a standard. For CEA determination, specimens and human CEA standards were solubilized with 0.1% NP-40 and assayed in duplicate by enzyme-linked polyclonal immunoassay (ELISA, Abbott Laboratories, N. Chicago, IL).
Isopycnic sucrose densitygradients. Sucrose density gradient arialysis of LS-174T cell homogenate and concentrated serum-free 24-h culture medium was performed using a modification of the method of Knipe et al. (13) . Samples were made 55% sucrose (wt/vol) and 3 ml was overlaid with a 9-ml discontinuous gradient of sucrose prepared in buffer A containing 1 mM EDTA and 0.1 mM PMSF (buffer B). Gradients were centrifuged at 100,000 g for 16 h at 4°C and then collected from the bottom in 1.25-ml fractions. Fraction dehsities were determined with a model 10450 Abbe refractometer (American Optical Corp., Buffalo, NY).
Immunoprecipitation and immunoblotting. To immunoprecipitate CEA, 700 ,l of each sample was combined with 700 ul of buffer C (10 mM Tris-HCI, pH 7.6, 0.5 M NaCI, 1 mg/ml BSA, 1% NP-40, 1 mM EDTA, and 0.1 mM PMSF). Immunoprecipitation of CEA in human serum samples was preceded by incubation with 1 ml of 10% PASA for 1 h at 4°C and centrifugation at 600 g for 10 min in order to remove human immunoglobulins. In the experiments using radioactive precursors, aliquots of membranes were used containing equal trichloroacetic acid-precipitable counts per minute. Immunoprecipitation was performed as described previously (14) Triton X-114 detergent partitioning. Detergent partitioning with Triton X-1 14 was performed using a modification of the method of Bordier (16) . Samples (235 ,l) were combined with 175 Ml of buffer A and 90 Ml of 5% Triton X-1 14. This was vortexed, sonicated for lO s on ice, overlaid on a 750-,ul cushion of9% sucrose in buffer B (wt/vol) in a 12 X 75-mm tube, and then partitioned into detergent and aqueous layers at 30°C as described (16) . The lower 250-Mul ofthe final detergent layer was used as the detergent phase in subsequent analyses, and the upper 500 Ml of the final aqueous layer was used as the aqueous phase. Each phase was analyzed for CEA content using immunoprecipitation followed by SDS-PAGE and immunoblotting. Based upon experiments using BSA as a standard protein, separation of hydrophobic from hydrophilic macromolecules was complete under these conditions (not shown).
Incubation of membranes with proteases and phospholipases. 235 Ml of LS-174T cell membranes was thawed, sonicated for 10 s, combined with 175 M1 of a protease or phospholipase solution (in buffer A except where stated otherwise), and incubated for 6 h at 37°C in a rapidly shaking water bath. After incubation, reactions were stopped by rapidly cooling to 4°C and adding 22 Ml of the appropriate enzyme inhibitor. The final concentration of inhibitor for each protease (in parentheses) was 4 mM benzamidine (trypsin and elastase), 0.4 mM ZPCK (chymotrypsin), 5 mM EDTA (carboxypeptidase-B), and 4 mM iodoacetate (papain and bromelain).
Incubation ofcolon cancer cell monolayers and human cancerspecimens with PI-PLC. Confluent LS-174T monolayers were washed three times with DME, incubated for 6 h at 37°C with DME or with DME containing PI-PLC from B. thuringiensis (3 U/ml), and the cells and medium were harvested for CEA determination by ELISA. Frozen human colon cancer specimens were minced finely at 4°C, washed three times with iced DME, and incubated with DME or with DME containing PI-PLC as described above. The samples then were centrifuged at 100,000 g at 4°C for 1 h, and the pellets and supernates were assayed for CEA content by ELISA to determine cell content and CEA release, respectively.
Results
CEA release and cell viability. Confluent LS-1 74T cell monolayers released -30% of their cellular CEA content into the culture medium in 24 h (Fig. 1 ). This release rate was observed using medium containing 5% FBS or with serum-free medium supplemented with growth factors (not shown). In order to determine that CEA release was not due to cell death, CEA release was compared with the release of the cytosolic enzyme A 30 Figure1. Rate 24 -h culture medium was performed and the CEA content of each fraction determined by CEA immunoprecipitation and immunoblotting. Cellular CEA floated upwards to the region of the gradient with a density of -1.14-1.16 g/ml (Fig. 2 A) , the buoyant density of plasma membranes (18) . In contrast, most of the medium Gradient fractions were analyzed for CEA content using CEA immunoprecipitation followed by immunoblotting and autoradiography. The intensity of the 180-kD bands was determined by densitometer and the density of each fraction was determined using a refractometer.
CEA remained at the bottom of the tube in the high-density zone, with only a small portion rising to the low-density region (Figure 2 B) . This suggests that cellular CEA is membrane associated, while CEA released into the medium is a soluble glycoproteih.
To further characterize released CEA, freshly harvested 24-h culture medium was applied to a Sepharose CL-4B column and eluted with PBS containing 0.1 mM PMSF at room temperature (Fig. 3) . Medium CEA eluted as an aggregate of -500 kD; only a small proportion appeared in the void volume where membranous material would be expected to elute ( 19).
Triton X-1 14 partitioning of cell homogenate and serumfree 24-h culture medium whs performed next, followed by immunoprecipitation with anti-CEA, SDS-PAGE, and immunoblotting (Fig. 4) ciated CEA to the form observed after its release into the culture medium and into patient sera.
High concentrations of proteases had no effect upon the hydrophobicity of cellular CEA (Fig. 5 A) . The same results were obtained when membranes were sonicated with 1% Triton X-1 14 for 20 s at 4VC before incubation with the enzymes (not shown), indicating that the failure of proteases to affect the molecular form of CEA is unlikely to be due to a lack of access ofthe enzymes to CEA cleavage sites. That the enzymes were proteolytically active under these conditions was verified with the protease assay of Beynon et al. (20) using azocasein as substrate (results not shown). Fig. 5 B shows the results of incubating cell membranes with different buffers and phospholipases. Incubation with 1 M NaCl did not alter CEA hydrophobicity, indicating that ionic interactions are not responsible for this aspect of the molecular form of CEA. Phospholipase D (from cabbage) and phospholipase A2 (from Naja naja), incubated under the conditions optimal for each enzyme, also had no effect. However, incubation with 5 U/ml of partially purified PLC from B. cereus efficiently converted all the CEA to the hydrophilic form.
Two types of PLC produced by B. cereus have been described, a phosphatidylinositol-specific PLC (PI-PLC) and a broad-specificity PLC which cleaves the phosphodiester bond of phosphatidylcholine and certain other phospholipids but not of phosphatidylinositol (2 1). Commercial preparations of B. cereus PLC contain variable amounts of PI-PLC (22) . To determine which PLC is responsible for changing the molecular form of CEA, incubations were performed with PLC of B.
cereus in the presence of a high concentration of o-phenanthroline, an inhibitor of the broad-specificity PLC (22) . Membrane CEA was fully converted to the hydrophilic form in the presence of 0.5 mM o-phenanthroline, suggesting that the changes in CEA hydrophobicity caused by this preparation of B. cereus PLC are due to PI-PLC activity (Fig. 5 C) . The inhibitor also had no effect when incubations were performed using a rate-limiting concentration of the B. cereus PLC (0.5 U/ml). In addition, bacterial PI-PLC purified from B. thuringiensis and S. aureus each converted membrane-associated CEA to the hydrophilic form (Fig. 5 C) CEA release from LS-J 74T monolayers and human colon cancer specimens. The ability of PI-PLC to release CEA from intact LS-1 74T cells and from previously frozen human colon cancer specimens was studied by incubating confluent monolayers or minced colon cancer specimens with serum-free DME in the presence or absence of PI-PLC from B. thuringiensis (Table III) . For the monolayers, CEA assays were performed on the cells and medium at 3 and 6 h ofincubation; the cancer specimens were ultracentrifuged after 3 h and assays performed on the pellets and supernatants. treatment released substantial amounts of the cellular CEA from seven human colon cancer specimens (Table III) . Triton X-1 14 partitioning ofcolon cancer sera. Serum specimens obtained from five patients with colon cancer were analyzed by Triton X-114 partitioning (Fig. 7) . The samples were selected because of their unusually high CEA concentrations (see legend to Fig. 5 ), which is necessary for accurate CEA detection using these methods. In these experiments, the CEA in LS-174T cell membranes, which was used as a control, partitioned exclusively into the hydrophobic, detergent phase. In contrast, each serum sample contained substantial amounts of CEA which partitioned into the aqueous phase and resembled the CEA released by colon cancer cells in vitro. No bands were seen using control serum samples containing < 5 ng CEA/ml (not shown). In addition to the hydrophilic CEA, most samples contained hydrophobic CEA. The presence of both molecular forms of CEA suggests that there may be more than one mechanism for CEA release from colon cancers in vivo.
In antigen-2, which are expressed by normal human leukocytes as well as by some colon cancers (1) and which are known to be immunoprecipitated by the antiserum used (24) .
Discussion
Four mechanisms have been proposed for the release of membrane-associated glycoproteins in vivo, including cell lysis (25) , shedding of plasma membrane vesicles (25, 26) , cleavage by proteases (25) , and release due to the action of phospholipases (7, 23) . The present experiments were designed to determine the nature of the membrane-binding domain of CEA and to study the mechanism of CEA release in vitro and in vivo. The results suggest that CEA is attached to membranes by a glycosyl-phosphatidylinositol linkage and that an endogenous phospholipase may be responsible for the release of human colon cancer CEA.
We first established that CEA release by the human colon cancer cell line LS-1 74T is an active process not accompanied by significant LDH release (Table I) or light-microscopic evidence of impairment of plasma membrane integrity. Cellular CEA is predominantly membrane bound and hydrophobic, based upon its buoyant density and partitioning into the detergent phase of a Triton X-114-water mixture (16) . The interaction with membranes appears to be nonionic since CEA is not dislodged from cell membranes with hypertonic or hypotonic buffers (Fig. 5 B) . In contrast, released CEA is a soluble, hydrophilic molecule, indicating that CEA release is associated with a change in CEA molecular form.
Significant amounts of membrane vesicles containing CEA were not detected in the medium by ultracentrifugation or by Sepharose CL-4B chromatography. Therefore, neither cell death nor membrane vesiculation is responsible for CEA release by LS-1 74T cells.
Several studies have demonstrated that exogenous proteases, including trypsin, elastase, papain, and bromelain, will release cell surface glycoproteins in vitro (27) (28) (29) (30) . In addition, there are endogenous proteases on gastrointestinal cells which could, in principle, play a role in glycoprotein release (31, 32) . However, extensive incubation of LS-174T cell membranes with different proteases had no effect upon CEA hydrophobicity or solubility despite using more exhaustive incubation conditions than those reported previously (28) (29) (30) (31) .
Of the six phospholipase preparations incubated with cell membranes, only the three PI-PLCs converted CEA to the hydrophobic form or released significant amounts from cell membranes. It is unlikely that these results are due to the presence of contaminating proteases. Each PI-PLC preparation was free of protease activity when tested using azocasein as substrate (20) . In addition, no proteolysis was detected when the B. cereus PLC preparation was incubated with BSA, human immunoglobulin G, or human insulin for 6 h followed by SDS-PAGE and Coomassie Blue staining (results not shown).
The ability of PI-PLC to release CEA from LS-174T cell membranes, from living LS-174T cells in culture, and from specimens of human colon cancers indicates that CEA is anchored to cell membranes by covalently linked phosphatidylinositol. This mechanism of membrane attachment has been proposed recently for several other cell surface glycoproteins (23) . These glycoproteins are attached to membranes by an amide bond between the COOH-terminus amino acid of the glycoprotein and a short linking oligosaccharide which is covalently linked to the inositol head group of an intramembranal phosphatidylinositol (22) . The fatty acids of phosphatidylinositol anchor the glycoprotein and make it hydrophobic. Consistent with the present results for CEA, glycoproteins in this class can all be released from membranes in vitro by incubation with preparations of purified bacterial PI-PLC (23, 27) and release by PI-PLC is associated with the conversion of the glycoprotein to a hydrophilic form. It is also characteristic of these glycoproteins that release is associated with no change in molecular weight detectable by conventional 7% PAGE since only a diacylglycerol moiety is removed (23) .
The composition of the linking oligosaccharide has been determined partially for two of these glycoproteins-mouse Thy-l and variant surface glycoprotein (VSG) of Trypanosoma brucei-and found to contain stoichiometric amounts of ethanolamine, mannose, galactose, and glucosamine (22, 33, 34) . Our data showing that membrane-bound CEA incorporates both [3H]ethanolamine and [3H]palmitate, and that only the latter is released by PI-PLC, is further evidence that CEA contains the glycosyl-phosphatidylinositol structure (Fig. 6) .
Another feature of this attachment mechanism that we have observed for CEA is that treatment with PI-PLC usually releases the majority, but not all, of the membrane-bound glycoprotein (23, 27) . Two hypotheses have been proposed to explain this finding. First, some glycoproteins, such as the neural cell adhesion molecule (N-CAM), can be anchored by either glycosyl-phosphatidtylinositol or by a hydrophobic peptide sequence (35) . Second, human erythrocyte membrane acetylcholinesterase has been reported to have a palmitic acid residue substituted at the 2-OH of the inositol ring (23, 36) . Modifications such as this may be responsible for the observed partial resistance to PI-PLC (23) . In the case of CEA, the removal of [3H]palmitate by PI-PLC (Fig. 6 ) makes a palmitic acid substitution unlikely but does not rule out either of the aforementioned hypotheses.
These results for CEA are the first evidence that a tumorassociated glycoprotein may be released by a phospholipase under physiological conditions. In the cases of other glycosylphosphatidylinositol-linked glycoproteins for which the release mechanism has been studied, it is uncertain whether release by endogenous phospholipases occurs in intact cells and whether the enzyme responsible is a phospholipase C or phospholipase D (37) (38) (39) . The release of VSG caused by the T. brucei PI-PLC is only observed under conditions of osmotic or cold detergent lysis (40) , and the phospholipase D-like activity described recently in the serum of several mammalian species, including humans, releases VSG from T. brucei only in the presence of detergent (37, 38) . Similarly, the release of placental alkaline phosphatase from human placenta by an endogenous phospholipase D requires activation by butanol or detergent (35) . Serum from patients with colon cancer contains substantial quantities of hydrophilic CEA (Fig. 7) , suggesting that an endogenous phospholipase releases CEA in vivo. However, hydrophobic CEA was also detected in most specimens. We interpret this as indicating that more than one release mechanism may be operative in vivo: hydrophilic CEA results from phospholipase action and hydrophobic CEA may be the result of cancer cell death which releases CEA into the circulation still attached to the hydrophobic phosphatidylinositol anchor.
Because LS-174T cells release CEA in the hydrophilic form when incubated in serum-free medium, it is not likely that the hydrophilic CEA observed in human serum was released from cells in a hydrophobic form and subsequently converted to the hydrophilic form by a serum phospholipase. Further experiments are in progress to address these questions.
